Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children

In this study, the introduction of guidelines-based therapy in all children decreased the number of days per fortnight that children had asthma symptoms. Treatment with omalizumab resulted in fewer days with asthma symptoms than placebo. Studies of inner-city children, adolescents, and young adults with asthma show that symptom control is improved and exacerbations are decreased when there is either a reduction in household exposure to allergens 1 or aggressive implementation of guidelines-based therapy. 2 Nonetheless, achieving disease control remains difficult, necessitating a need for additional treatment. For patients with allergies who have asthma that is not controlled with implementation of the higher treatment steps of the most recent guidelines from the National Asthma Education and Prevention Program (NAEPP) (Expert Panel Report 3), omalizumab, a humanized monoclonal anti-IgE antibody, is recommended. 3 – 9 Anti-IgE treatment reduces exacerbations, symptoms and, . . .